Browse related articlesNew diabetes drug uses artificial venom
Wednesday, February 20 - 2008 at 07:54
A new Type 2 diabetes drug now available in the UAE uses an artificial version of the venom found in the Gila Monster, reported Gulf News. The saliva of the two-feet long pink and black lizard, native to the US, contains a chemical exendin-4, similar to a human hormone to help regulate blood sugar. The drug, Exenatide (Byetta), has proven effective in the control of Type 2 diabetes in humans.
See Also
Also consider reading:
- » Yemen, Cuba discuss health cooperation
- » Oman to hold childhood cancer conference
- » Shortage of brains and hearts in Saudi
- » UAE plans new rules for tobacco companies
- » HMSDC credits recognized by UAE authorities
- » Abu Dhabi puts freeze on shisha cafes
- » Bahrain sets health centers for the disabled
- » Alturki ventures in eco services
- » Abu Dhabi to launch electronic claims
- » Egypt to ban nurses from wearing veil
Facebook
LinkedIn
Digg
Jeff Florian, Senior ReporterWednesday, February 20 - 2008 at 07:54 UAE local time (GMT+4)
Replication or redistribution in whole or in part is expressly prohibited without the prior written consent of AME Info FZ LLC / Emap Limited.
Disclaimer:
The information comprised in this section is not, nor is it held out to be, a solicitation of any person to take any form of investment decision. The content of the AME Info Web site does not constitute advice or a recommendation by AME Info FZ LLC / Emap Limited and should not be relied upon in making (or refraining from making) any decision relating to investments or any other matter. You should consult your own independent financial adviser and obtain professional advice before exercising any investment decisions or choices based on information featured in this AME Info Web site.
AME Info FZ LLC / Emap Limited can not be held liable or responsible in any way for any opinions, suggestions, recommendations or comments made by any of the contributors to the various columns on the AME Info Web site nor do opinions of contributors necessarily reflect those of AME Info FZ LLC / Emap Limited.
In no event shall AME Info FZ LLC / Emap Limited be liable for any damages whatsoever, including, without limitation, direct, special, indirect, consequential, or incidental damages, or damages for lost profits, loss of revenue, or loss of use, arising out of or related to the AME Info Web site or the information contained in it, whether such damages arise in contract, negligence, tort, under statute, in equity, at law or otherwise.
The information comprised in this section is not, nor is it held out to be, a solicitation of any person to take any form of investment decision. The content of the AME Info Web site does not constitute advice or a recommendation by AME Info FZ LLC / Emap Limited and should not be relied upon in making (or refraining from making) any decision relating to investments or any other matter. You should consult your own independent financial adviser and obtain professional advice before exercising any investment decisions or choices based on information featured in this AME Info Web site.
AME Info FZ LLC / Emap Limited can not be held liable or responsible in any way for any opinions, suggestions, recommendations or comments made by any of the contributors to the various columns on the AME Info Web site nor do opinions of contributors necessarily reflect those of AME Info FZ LLC / Emap Limited.
In no event shall AME Info FZ LLC / Emap Limited be liable for any damages whatsoever, including, without limitation, direct, special, indirect, consequential, or incidental damages, or damages for lost profits, loss of revenue, or loss of use, arising out of or related to the AME Info Web site or the information contained in it, whether such damages arise in contract, negligence, tort, under statute, in equity, at law or otherwise.
Web Feeds